Table 1. Respondent characteristics.

Characteristics		All		Inflammatory rheumatic disease patients	
		(n=591)	(%)	(n=453)	(%)
Biologics	Female gender, <i>n</i> (%)	353	(59.7)	286	(63.1)
	Age, median (IQR), years	59.0	(51.0-67.0)	60.0	(51.0-67.5)
	Adalimumab	220	(37.2)	164	(36.2)
	Etanercept	196	(33.2)	189	(41.7)
	Infliximab	43	(7.3)	8	(1.8)
	Tocilizumab	21	(3.6)	17	(3.8)
	Ustekinumab	21	(3.6)	7	(1.5)
Combination therapy	Other	90	(15.2)	68	(15.0)
	Methotrexate	195	(33.0)	183	(40.4)
Indications for biologic therapy	Corticosteroids	65	(11.0)	51	(11.3)
	Thiopurines	41	(6.9)	10	(2.2)
	No combination therapy	231	(39.1)	157	(34.7)
	Other	123	(20.8)	106	(23.4)
	Rheumatoid arthritis	277	(46.9)	277	(61.1)
	Psoriatic arthritis	111	(18.8)	111	(24.5)
	Ankylosing spondylitis/axSpA	83	(14.0)	83	(18.3)
	Other	159	(26.9)	17	(3.8)

IQR: interquartile range; axSpA: axial spondyloarthritis.

Figure 1. The preferences of patients on the communication of the reported adverse drug reaction information resulting from the Dutch Biologic Monitor.

Conclusion: Participants of the Dutch Biologic Monitor that use a biologic for their IMID prefer to receive ADR information tailored to their own biologic and IMID. Furthermore, they want to obtain insight in the course of ADRs. Therefore, we advocate to generate disease-specific information on ADRs for IMID patients.

References:

[1] Kosse LJ, Jessurun NT, Hebing RCF, Huisjes VJB, Spijkers KM, van den Bemt BJF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. *Rheumatol*. published on 30 Sept 2019. doi: 10.1093/rheumatology/kez412.

Disclosure of Interests: Gerda Weits: None declared, Leanne Kosse: None declared, Harald Vonkeman: None declared, Phyllis Spuls Grant/research support from: Departmental independent research grant for TREAT NL registry LeoPharma December 2019; Contract support: I am involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis for which we get financial compensation paid to the department/hospital, Consultant of: Consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), Bart van den Bemt Grant/research support from: UCB, Pfizer and AbbVie, Consultant of: Delivered consultancy work for UCB, Novartis and Pfizer, Speakers bureau: Pfizer, AbbVie, UCB, Biogen and Sandoz., Sander Tas: None declared, Frank Hoenjens Grant/research support from: Received grants from Dr Falk, Janssen-Cilag, and AbbVie., Consultant of: Served on advisory boards, or as speaker or consultant for AbbVie, Celgene, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz, and Dr Falk, Michael Nurmohamed Grant/research support from: Not related to this research, Consultant of: Not related to this research, Speakers bureau: Not related to this research, Martijn van Doorn Grant/research support from: Unrestricted grants, advisory board, speaker fees and/or other (investigator) from Novartis, AbbVie, Janssen Cilag, Leopharma and Pfizer, Speakers bureau: Unrestricted grants, advisory board, speaker fees and/or other (investigator) from Novartis, AbbVie, Janssen Cilag, Leopharma and Pfizer, Eugène van Puijenbroek: None declared, Naomi Jessurun: None declared

DOI: 10.1136/annrheumdis-2020-eular.1841

OP0269-HPR ASSOCIATION OF SARC-F PERFORMANCE WITH COMORBIDITIES, PHYSICAL DISABILITY AND LOWER ALBUMIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS

L. Santos^{1,2}, R. Cavalheiro Do Espírito Santo^{1,2}, V. Hax^{1,2}, R. Mendonça Da Silva Chakr^{1,2}, R. Xavier^{1,2}, ¹Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, Brazil; ²Hospital de Clínicas de Porto Alegre - HCPA, Division of Rheumatology, Porto Alegre, Brazil

Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease of complex etiopathogeny, heterogeneous in its phenotypic expression and with a limited prognosis (1). The loss of muscle mass is a serious consequence of many chronic diseases and also is observed in SSc (2). This body composition alterations results in weakness, limitations and physical disability (3). SARC-F simple questionnaire, validated, is a key diagnostic feature for the fast assessment of geriatric syndromes associated with skeletal muscle wasting. However, there is no data about the SARC-F in SSc.

Objectives: To assess the association between the SARC-F questionnaire with clinical features in patients with systemic sclerosis (SSc).

Methods: Ninety-four patients diagnosed with systemic sclerosis were recruited and evaluated. Sarcopenia was assessed by the SARC-F questionnaire. Clinical features as disease duration time, comorbidities, body mass index (BMI), functional capacity by the Health Assessment Questionnaire (HAQ), inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatine phosphokinase (CPK), hemoglobin, creatinin and albumin) were medical record. Frequency analysis, descriptive analysis and Pearson's correlation were performed. Statistical significance was considered as p<0.05.

Results: Of the 94 patients analyzed, most were women (87/94;92.6%) with mean age of 60.5±10.3 years, median disease duration time of 11.2 (7.5-18.9) and median number of comorbidities was 1.00 (1.00-2.00). The mean of BMI was 25.9±4.7 Kg/m². Twenty-one of the patients were classified as active or passive smokers, thirty-five said they were former smokers and thirty-eight never smoked. Sixty-nine (80, 2%) out of the ninety-four patients in the study had at least one type of comorbidity (mean 1, 44±1, 04). Eighty-three patients (88.3%) showed a SARC-F score without signs suggestive of sarcopenia (0-5) and eleven patients (11.7%) showed suggestive to sarcopenia (6-10). In HAQ, fifty-seven (60.6%) patients had mild incapacity, thirty-five (37.2%) had moderate incapacity, and two patients (2.2%) had severe incapacity. Higher SARC-F scores were associated with greater number of comorbidities (r=0.2; p=0.027), higher physical disability by HAQ (r= 0.5;p=0.000) and lower albumin levels (r= -0.3; p= 0.048). On other hand, SARC-F was not associated with time of diagnosis, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatine Phosphokinase (CPK), hemoglobin, hematocrit and creatinine.

Conclusion: SARC-F scores were associated with comorbidities, physical disability and lower albumin levels in systemic sclerosis patients. Considering that comorbidities, physical disability and the albumin deficit enhances the patient's muscle loss, SARC-F appears to be a good tool to screen sarcopenia risk factors in systemic sclerosis patients. Longitudinal studies are necessary to validate the SARC-F questionnaire in this population.

References:

[1] Hochberg MC et al. Sixth edit. (Elsevier, ed.). Philadelphia; 2015;
[2] Sakuma K et al. Pflügers Arch - Eur J Physiol. 2017;469(5-6):573-591.
[3] Caimmi C, et al. Clin Rheumatol. 2018;37(4):987-997.

Acknowledgments: We thank the Coordination for the Improvement of Higher Level Personnel (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—CAPES) institution, the Foundation for Research Support of the Rio Grande do Sul State (Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul—FAPERGS), the Research and Events Incentive Fund (Fundo de Incentivo à Pesquisa e Eventos—FIPE) of HCPA and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq).

Disclosure of Interests: Leonardo Santos: None declared, Rafaela Cavalheiro do Espírito Santo: None declared, Vanessa Hax: None declared, Rafael Mendonça da Silva Chakr: None declared, Ricardo Xavier Consultant of: AbbVie, Pfizer, Novartis, Janssen, Eli Lilly, Roche

DOI: 10.1136/annrheumdis-2020-eular.3800

Other orphan diseases

OP0270 TRHEUMA REGISTRY EXPLORES CHARACTERISTICS AND SUITABLE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS (IRAES)

K. Benesova¹, L. Diekmann¹, H. M. Lorenz¹, K. Jordan¹, J. Leipe². ¹University Hospital Heidelberg, Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany; ²University Hospital Mannheim, Division of Rheumatology, Department of Medicine V, Mannheim, Germany

Background: Reports of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICPi) have recently attracted new attention to the complex interrelations of malignancies and *rheumatic and musculoskeletal diseases (RMDs)*. Since those two entities represent two sides of a dysregulated immune response, further research on rheumatic irAEs and mechanisms underlying the better tumor response rates in irAE-affected patients may contribute to a better understanding of the different pathophysiology characterizing tumor and rheumatic disease.

Objectives: Given the heterogeneity of the patient population with rheumatic irAEs, a registry-based study has been conducted to provide first evidence regarding characteristics of rheumatic irAEs and further insights into the optimal diagnostic and therapeutic management of rheumatic irAEs.

Methods: The TRheuma registry is a long-term, open-end observational study of a patient cohort suffering from rheumatic symptoms as a result of ICPi or other cancer therapies. The TRheuma registry is one of the three subregistries of the Malheur project, a registry-based study initiated in July 2018 at the at the university hospital Heidelberg to explore interrelations of malignancies and RMDs.

Results: Over 18 months, 52 of 63 patients in the TRheuma registry were recruited with a rheumatic irAE under ICPi treatment (pembrolizumab n=21, nivolumab n=28, ipilimumab n=11, durvalumab n=1, atezolizumab n=2, avelumab n=1, history of >1 ICPi n=11). Of the 52 patients, 22 (42.3%) had non-small cell lung cancer and 23 (44.2%) had a melanoma. Eight (15.3%) patients experienced a flare of a preexisting RMD under ICPi treatment. The remaining 44 patients with *de novo* irAEs were characterized by rheumatoid arthritis-like (20.5%) or polymyalgia rheumatica-like (18.1%) and psoriatic or other spondyloarthritis-like phenotypes (50.0%). However, laboratory findings differed from classical RMDs with elevated CRP-levels in 73.1% particularly in psoriatic arthritis-like, but not necessarily in polymyalgia rheumatica-like irAEs. On the contrary, autoantibody positivity was very rare. The majority of patients (78.8%) showed signs of inflammation upon ultrasound examination.

Based on the severity of signs and symptoms as well as treatment response, we developed a therapeutic algorithm for rheumatic irAEs: non-steroidal anti-inflammatory drugs and/or low dosed glucocorticoids ($\leq 10\text{mg}$ prednisone equivalent) as first treatment step were sufficient for 75% patients, whereas 17.3% required higher dosed glucocorticoids and 11.5% patients required further treatment with a cs- or bDMARD. In two cases ICPi-treatment was discontinued on patients' request due to the pain and functional impairment caused by the rheumatic irAE, although a satisfactory symptom control was reached in the further course.

Complete remission of cancer was observed in 43.5% of melanoma patients, 66.7% experienced additional severe irAEs in other organ systems.

Conclusion: Overall, data from the TRheuma-registry show that rheumatic irAEs mostly resemble classical RMDs, however show distinct characteristics. Our diagnostic and therapeutic management of rheumatic irAEs demonstrated efficacy in the majority of patients. These findings contribute to the further understanding of rheumatic irAEs and malignancies. Future research agenda includes a correlation of irAE severity with tumor response.

Disclosure of Interests: Karolina Benesova Grant/research support from: Study grants for SCREENED study by Abbvie, Novartis and Rheumaliga Baden-Württemberg, Consultant of: One-time participation in Novartis advisory board., Leonore Diekmann: None declared, Hanns-Martin Lorenz Grant/research support from: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharma, Thermo Fisher., Consultant of: see above, Karin Jordan Consultant of: Consultancy and/or speaker fees: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntas, Pfizer, Pomme-med., Jan Leipe Grant/research support from: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer., Speakers bureau: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB

DOI: 10.1136/annrheumdis-2020-eular.3790

OP0271

REAL-WORLD CLINICAL BURDEN AND GLUCOCORTICOID USE IN PATIENTS WITH POLYMYALGIA RHEUMATICA

R. Puneekar¹, P. Lafontaine², J. H. Stone³. ¹Sanofi, Cambridge, United States of America; ²Sanofi, Bridgewater, United States of America; ³Harvard Medical School, Boston, United States of America

Background: Polymyalgia rheumatica (PMR) is a chronic inflammatory condition characterized by aching and morning stiffness in the neck, shoulders and

pelvic girdle. It is a common inflammatory rheumatic disease in patients age >50 years, particularly women. While giant cell arteritis (GCA) is present in 9–21% of PMR cases, many PMR patients have symptoms independent of GCA. Current treatment options are limited to long-term glucocorticoid (GC), however, with risks of GC-related complications, including cardiovascular disease, osteoporosis, and diabetes mellitus.

Objectives: To compare GC use and subsequent GC-related complications in patients with PMR vs a general population (GnP) cohort.

Methods: This retrospective, observational cohort study was based on Optum's de-identified Clinformatics® Data Mart Database (study period 01Jan2006–30June2018). The PMR cohort included patients with ≥ 1 inpatient or ≥ 2 outpatient claims ≥ 30 days apart with PMR related diagnosis codes (ICD-9: 725.xx or ICD-10: M35.3x) between 01Jan2006–30June2017 (patient identification period) during which first occurrence of a PMR-related medical claim was set as the index date (ID). Patients with ≥ 1 medical claim related to rheumatoid arthritis (RA) or GCA during the study period were excluded. The GnP cohort included patients without any RA, GCA or PMR diagnosis codes during the study period, with their ID set as 12 months from the start of continuous health plan enrollment. Patients in both cohorts were required to be age ≥ 50 years (on ID) with continuous health plan enrollment ≥ 12 months pre- and post-ID. Cohorts were 1:1 propensity score matched. GC use and incidence of GC-related complications were assessed from GC initiation, starting from the baseline period (12-months pre-ID) through to the end of GC use during the post-index period (i.e. the end of data availability, end of the study period or death [whichever occurred first]). Mean, standard deviation (SD) and median values for continuous variables, and frequency (n and %) for categorical variables were compared between the matched cohorts. Wilcoxon sum rank tests and t-tests on continuous variables and Chi-square tests or Fisher's exact tests on categorical variables between matched cohorts were conducted. Duration of GC use was analyzed using the Kaplan-Meier method and compared between matched cohorts using log-rank tests.

Results: In each of the PMR and GnP cohorts, 16,865 patients were included. In both matched cohorts, median age was 76 years, median Elixhauser comorbidity index score was 2.0, and the majority (~65%) were women. The median follow-up duration was 45 months and 51 months in the PMR and GnP cohorts, respectively. A higher proportion of patients in the PMR cohort than the matched GnP cohort (90.4% vs 62.8%; $p < 0.001$) used GC. The mean (SD) duration of GC therapy was significantly longer in the PMR cohort than in the matched GnP cohort (242.1 [± 317.2] days vs 35.5 [± 124.6] days; $p < 0.001$). Although patients in the PMR cohort had a lower average daily dose of GC (prednisone equivalent) vs the GnP cohort (mean [SD] mg 16.3 [± 21.9] vs 27.8 [± 24.5], respectively [$p < 0.0001$]), the cumulative GC dose was significantly higher in the PMR cohort than the GnP cohort (2125.4 [± 3689.5] mg vs 476.6 [± 1450.9] mg; $p < 0.001$). This indicates PMR patients used chronic low dose GC while the GnP patients utilized higher dose GC burst therapy less frequently. The number of incident complications associated with GC use were significantly greater in the PMR cohort, and included hypertension, diabetes, skin toxicity, infections, neuropsychiatric effects, endocrine abnormalities, renal dysfunction/failure, ocular effects, and cardiovascular disease ($p < 0.05$).

Conclusion: The overall GC burden in patients with PMR is high. With a higher incidence of GC-related comorbidities among PMR patients, early onset of these complications may be a significant contributor to long-term healthcare costs in these patients.

Acknowledgments: This study was funded by Sanofi, Inc. Medical writing, under the direction of authors, was provided by Gauri Saal, MA Economics, Prime, Knutsford, UK, and funded by Sanofi.

Disclosure of Interests: Rajeshwari Puneekar Shareholder of: Sanofi, Employee of: Sanofi, Patrick LaFontaine Shareholder of: Sanofi, Employee of: Sanofi, John H. Stone Grant/research support from: Roche, Consultant of: Roche

DOI: 10.1136/annrheumdis-2020-eular.4285

OP0272

LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL

S. Özen¹, E. Ben-Chetrit², I. Foeldvari³, G. Amariljo⁴, H. Ozdogan⁵, S. Vanderschueren⁶, K. Marzan⁷, J. M. Kahlenberg⁸, E. Dekker⁹, F. De Benedetti¹⁰, I. Koné-Paut¹¹. ¹Hacettepe University, Department of Pediatric Rheumatology, Ankara, Turkey; ²Hadassah-Hebrew University Medical Center, Rheumatology Unit, Jerusalem, Israel; ³Hamburg Centre for Pediatric and Adolescent Rheumatology, An der Schön Klinik, Hamburg, Germany; ⁴Schneider Children's Medical Center of Israel, Tel Aviv, Israel; ⁵University of Istanbul-Cerrahpaşa, Department of Medicine, Istanbul, Turkey; ⁶University Hospitals Leuven, Leuven, Belgium; ⁷Children's Hospital Los Angeles, Los Angeles, United States of America; ⁸University of Michigan, Department of